Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "NITI"

3482 News Found

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026
Biotech | March 07, 2026

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations


CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park
News | March 06, 2026

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park

The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant


Shyamakant Giri resigns as CEO of Gland Pharma
People | March 05, 2026

Shyamakant Giri resigns as CEO of Gland Pharma

Giri stated he is stepping down to pursue new opportunities after careful consideration


KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients
News | March 05, 2026

KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients

Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention


Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Clinical Trials | March 03, 2026

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings


AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
Clinical Trials | March 03, 2026

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population


Dabur backs luxury skincare startup RAS Beauty with Rs 60 crore investment
News | March 03, 2026

Dabur backs luxury skincare startup RAS Beauty with Rs 60 crore investment

The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins


FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
News | March 03, 2026

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications